Humoral and cellular immune responses to CoronaVac up to one year after vaccination
Coronavac is a widely used SARS-CoV-2 inactivated vaccine, but its long-term immune response assessment is still lacking. We evaluated SARS-CoV-2-specific immune responses, including T cell activation markers, antigen-specific cytokine production and antibody response following vaccination in 53 adu...
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-10-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.1032411/full |
| _version_ | 1811337147752382464 |
|---|---|
| author | Priscilla Ramos Costa Carolina Argondizo Correia Mariana Prado Marmorato Juliana Zanatta de Carvalho Dias Mateus Vailant Thomazella Amanda Cabral da Silva Ana Carolina Soares de Oliveira Arianne Fagotti Gusmão Lilian Ferrari Angela Carvalho Freitas Elizabeth González Patiño Alba Grifoni Daniela Weiskopf Alessandro Sette Alessandro Sette Rami Scharf Esper Georges Kallás Esper Georges Kallás Cássia Gisele Terrassani Silveira |
| author_facet | Priscilla Ramos Costa Carolina Argondizo Correia Mariana Prado Marmorato Juliana Zanatta de Carvalho Dias Mateus Vailant Thomazella Amanda Cabral da Silva Ana Carolina Soares de Oliveira Arianne Fagotti Gusmão Lilian Ferrari Angela Carvalho Freitas Elizabeth González Patiño Alba Grifoni Daniela Weiskopf Alessandro Sette Alessandro Sette Rami Scharf Esper Georges Kallás Esper Georges Kallás Cássia Gisele Terrassani Silveira |
| author_sort | Priscilla Ramos Costa |
| collection | DOAJ |
| description | Coronavac is a widely used SARS-CoV-2 inactivated vaccine, but its long-term immune response assessment is still lacking. We evaluated SARS-CoV-2-specific immune responses, including T cell activation markers, antigen-specific cytokine production and antibody response following vaccination in 53 adult and elderly individuals participating in a phase 3 clinical trial. Activated follicular helper T (Tfh), non-Tfh and memory CD4+ T cells were detected in almost all subjects early after the first vaccine dose. Activated memory CD4+ T cells were predominantly of central and effector memory T cell phenotypes and were sustained for at least 6 months. We also detected a balanced Th1-, Th2- and Th17/Th22-type cytokine production that was associated with response over time, together with particular cytokine profile linked to poor responses in older vaccinees. SARS-CoV-2-specific IgG levels peaked 14 days after the second dose and were mostly stable over one year. CoronaVac was able to induce a potent and durable antiviral antigen-specific cellular response and the cytokine profiles related to the response over time and impacted by the senescence were defined. |
| first_indexed | 2024-04-13T17:50:40Z |
| format | Article |
| id | doaj.art-925809275d9f4002aa7861437b07f13c |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-13T17:50:40Z |
| publishDate | 2022-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-925809275d9f4002aa7861437b07f13c2022-12-22T02:36:44ZengFrontiers Media S.A.Frontiers in Immunology1664-32242022-10-011310.3389/fimmu.2022.10324111032411Humoral and cellular immune responses to CoronaVac up to one year after vaccinationPriscilla Ramos Costa0Carolina Argondizo Correia1Mariana Prado Marmorato2Juliana Zanatta de Carvalho Dias3Mateus Vailant Thomazella4Amanda Cabral da Silva5Ana Carolina Soares de Oliveira6Arianne Fagotti Gusmão7Lilian Ferrari8Angela Carvalho Freitas9Elizabeth González Patiño10Alba Grifoni11Daniela Weiskopf12Alessandro Sette13Alessandro Sette14Rami Scharf15Esper Georges Kallás16Esper Georges Kallás17Cássia Gisele Terrassani Silveira18Medical Investigation Laboratory 60 (LIM-60), School of Medicine, University of São Paulo, São Paulo, BrazilMedical Investigation Laboratory 60 (LIM-60), School of Medicine, University of São Paulo, São Paulo, BrazilMedical Investigation Laboratory 60 (LIM-60), School of Medicine, University of São Paulo, São Paulo, BrazilMedical Investigation Laboratory 60 (LIM-60), School of Medicine, University of São Paulo, São Paulo, BrazilMedical Investigation Laboratory 60 (LIM-60), School of Medicine, University of São Paulo, São Paulo, BrazilMedical Investigation Laboratory 60 (LIM-60), School of Medicine, University of São Paulo, São Paulo, BrazilMedical Investigation Laboratory 60 (LIM-60), School of Medicine, University of São Paulo, São Paulo, BrazilMedical Investigation Laboratory 60 (LIM-60), School of Medicine, University of São Paulo, São Paulo, BrazilMedical Investigation Laboratory 60 (LIM-60), School of Medicine, University of São Paulo, São Paulo, BrazilDepartment of Infectious and Parasitic Diseases, Clinicas Hospital, School of Medicine, University of São Paulo, São Paulo, BrazilCenter for Clinical Trials and Pharmacovigilance Butantan Institute, São Paulo, BrazilCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, San Diego, CA, United StatesCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, San Diego, CA, United StatesCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, San Diego, CA, United StatesDepartment of Medicine, Division of Infectious Diseases and Global Public Health, University of California San Diego, San Diego, CA, United StatesPATH, Washington, DC, United StatesMedical Investigation Laboratory 60 (LIM-60), School of Medicine, University of São Paulo, São Paulo, BrazilDepartment of Infectious and Parasitic Diseases, Clinicas Hospital, School of Medicine, University of São Paulo, São Paulo, BrazilMedical Investigation Laboratory 60 (LIM-60), School of Medicine, University of São Paulo, São Paulo, BrazilCoronavac is a widely used SARS-CoV-2 inactivated vaccine, but its long-term immune response assessment is still lacking. We evaluated SARS-CoV-2-specific immune responses, including T cell activation markers, antigen-specific cytokine production and antibody response following vaccination in 53 adult and elderly individuals participating in a phase 3 clinical trial. Activated follicular helper T (Tfh), non-Tfh and memory CD4+ T cells were detected in almost all subjects early after the first vaccine dose. Activated memory CD4+ T cells were predominantly of central and effector memory T cell phenotypes and were sustained for at least 6 months. We also detected a balanced Th1-, Th2- and Th17/Th22-type cytokine production that was associated with response over time, together with particular cytokine profile linked to poor responses in older vaccinees. SARS-CoV-2-specific IgG levels peaked 14 days after the second dose and were mostly stable over one year. CoronaVac was able to induce a potent and durable antiviral antigen-specific cellular response and the cytokine profiles related to the response over time and impacted by the senescence were defined.https://www.frontiersin.org/articles/10.3389/fimmu.2022.1032411/fullCoronaVacvaccinationcellular responsehumoral responseimmune memory |
| spellingShingle | Priscilla Ramos Costa Carolina Argondizo Correia Mariana Prado Marmorato Juliana Zanatta de Carvalho Dias Mateus Vailant Thomazella Amanda Cabral da Silva Ana Carolina Soares de Oliveira Arianne Fagotti Gusmão Lilian Ferrari Angela Carvalho Freitas Elizabeth González Patiño Alba Grifoni Daniela Weiskopf Alessandro Sette Alessandro Sette Rami Scharf Esper Georges Kallás Esper Georges Kallás Cássia Gisele Terrassani Silveira Humoral and cellular immune responses to CoronaVac up to one year after vaccination Frontiers in Immunology CoronaVac vaccination cellular response humoral response immune memory |
| title | Humoral and cellular immune responses to CoronaVac up to one year after vaccination |
| title_full | Humoral and cellular immune responses to CoronaVac up to one year after vaccination |
| title_fullStr | Humoral and cellular immune responses to CoronaVac up to one year after vaccination |
| title_full_unstemmed | Humoral and cellular immune responses to CoronaVac up to one year after vaccination |
| title_short | Humoral and cellular immune responses to CoronaVac up to one year after vaccination |
| title_sort | humoral and cellular immune responses to coronavac up to one year after vaccination |
| topic | CoronaVac vaccination cellular response humoral response immune memory |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2022.1032411/full |
| work_keys_str_mv | AT priscillaramoscosta humoralandcellularimmuneresponsestocoronavacuptooneyearaftervaccination AT carolinaargondizocorreia humoralandcellularimmuneresponsestocoronavacuptooneyearaftervaccination AT marianapradomarmorato humoralandcellularimmuneresponsestocoronavacuptooneyearaftervaccination AT julianazanattadecarvalhodias humoralandcellularimmuneresponsestocoronavacuptooneyearaftervaccination AT mateusvailantthomazella humoralandcellularimmuneresponsestocoronavacuptooneyearaftervaccination AT amandacabraldasilva humoralandcellularimmuneresponsestocoronavacuptooneyearaftervaccination AT anacarolinasoaresdeoliveira humoralandcellularimmuneresponsestocoronavacuptooneyearaftervaccination AT ariannefagottigusmao humoralandcellularimmuneresponsestocoronavacuptooneyearaftervaccination AT lilianferrari humoralandcellularimmuneresponsestocoronavacuptooneyearaftervaccination AT angelacarvalhofreitas humoralandcellularimmuneresponsestocoronavacuptooneyearaftervaccination AT elizabethgonzalezpatino humoralandcellularimmuneresponsestocoronavacuptooneyearaftervaccination AT albagrifoni humoralandcellularimmuneresponsestocoronavacuptooneyearaftervaccination AT danielaweiskopf humoralandcellularimmuneresponsestocoronavacuptooneyearaftervaccination AT alessandrosette humoralandcellularimmuneresponsestocoronavacuptooneyearaftervaccination AT alessandrosette humoralandcellularimmuneresponsestocoronavacuptooneyearaftervaccination AT ramischarf humoralandcellularimmuneresponsestocoronavacuptooneyearaftervaccination AT espergeorgeskallas humoralandcellularimmuneresponsestocoronavacuptooneyearaftervaccination AT espergeorgeskallas humoralandcellularimmuneresponsestocoronavacuptooneyearaftervaccination AT cassiagiseleterrassanisilveira humoralandcellularimmuneresponsestocoronavacuptooneyearaftervaccination |